Shares of other companies:
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
April 17, 2024 Bitcoin Halving 2024: Market Impact Predictions
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
Apple Should Climb The Wall Of Worry
April 20, 2024
Microsoft Q3 Preview: Focusing On Copilot
April 19, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ACLX Stock News and Mentions of Arcellx, Inc. Stocktwits
Updated: April 23, 2024 (10:18)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Arcellx Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Arcellx, Inc. (ACLX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Arcellx stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Arcellx, Inc. (ACLX)
April 15, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Peering Into Arcellx's Recent Short Interest - Arcellx ( NASDAQ:ACLX )
Arcellx's ACLX short percent of float has risen 6.28% since its last report. The company recently reported that it has 3.77 million shares sold short, which is 8.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.9 days to cover their ...
In Article Trend: Somewhat-Bullish
April 4, 2024 (12:40) / "Zacks Commentary" (by Zacks Equity Research)
How Arcellx ( ACLX ) Stock Stands Out in a Strong Industry
Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
In Article Trend: Bullish
March 29, 2024 (18:57) / "Barrons"
Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors
Algonquin Power & UtilitiesStarboard Value increased its stake in the utility company to 62,141,000 shares. Starboard Value did so through the purchase of 150,000 Algonquin Power shares on Feb. 26 at a per share price of $5.73.
In Article Trend: Bullish
March 7, 2024 (19:52) / "Benzinga" (by Vandana Singh)
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - Arcellx ( NASDAQ:ACLX )
Morgan Stanley initiates Arcellx Inc ACLX, noting a differentiated CAR-T platform for blood cancer backed by an established CAR-T partner. ddBCMA ( aka anito-cel ) is Arcellx's lead asset, incorporating its patent-protected D-domain as the extracellular binding domain.
In Article Trend: Somewhat-Bullish
February 29, 2024 (13:03) / "Benzinga" (by Avi Kapoor)
Arcellx Analysts Boost Their Forecasts After Q4 Results - Arcellx ( NASDAQ:ACLX )
Arcellx, Inc. ACLX posted financial results for its fourth quarter on Wednesday. The company posted net income of $20.5 million for the quarter ended Dec. 31, 2023, compared to a year-ago net loss of $39.0 million.
In Article Trend: Neutral
February 29, 2024 (00:30) / "Zacks Commentary" (by Zacks Equity Research)
Arcellx, Inc. ( ACLX ) Q4 Earnings and Revenues Surpass Estimates
Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of 166.67% and 163.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
February 28, 2024 (21:00) / "PR Newswire" (by Arcellx)
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel ( formerly CART-ddBCMA ) in patients with relapsed or refractory multiple myeloma -- -- Ended the quarter with $729.2M, extending cash runway into 2027 --
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website